As the flagship journal of ESTRO we aim to publish the best science in the field of radiation oncology serving a multi-professional cancer community.
Joined June 2020
- Tweets917
- Following35
- Followers4K
- Likes32
The Green Journal is on LinkedIn, very active.
Just celebrating our 10k followers.
Follow us there if you want updates on our articles, special issues, new sections, and more!
linkedin.com/showcase/greenj…
cc @ESTRO_RT
Our @LinkedIn account has now more than 5,000 users, growing >1,600 new followers in the last 3 months.
Subscribe to our account linkedin.com/showcase/greenj… to get regular updates on our publications and initiatives!
cc @PBlanchardMD
Radiotherapy & Oncology retweeted
We’re moving our updates and conversations from Twitter X to LinkedIn! 🚀Follow us at TipsRO LinkedIn page linkedin.com/showcase/tipsro… to stay connected with the latest in technical innovations and patient support in radiation oncology. See you there! @ESTRO_RT @RO_GreenJournal
🚀 Thrilled to announce 3 new clinical trials in Radiotherapy & Oncology in partnership with @TheLancetOncol Lancet Oncology):
✨ ESO-SPARE
🔍 DBCG IMN2 post-hoc
📊 FAST-Forward nodal sub-study
More details coming soon! 👀 #ESTRO2025 #GreenJournal
We’re no longer posting here. Join us on LinkedIn for the latest updates! 📢
Catch our Editor-in-Chief Pierre Blanchard in a new interview on:
✨ The evolving role of journals
🤝 Cross-journal collaboration
🌱 Tips for early-career researchers
🔗 linkedin.com/feed/update/urn…
We are really looking forward to this session! Can't wait to see you all there!
A privilege to co-chair this @TheLancetOncol @RO_GreenJournal join session at #ESTRO2025 this weekend. See you there!
📢 Don’t miss the Green Journal–Lancet Oncology joint plenary at #ESTRO2025!
🗓 Sun May 4 | ⏰ 11:40–12:45
📍 Plenary Hall
Top clinical trials in GI & SBRT from 🇬🇧 🇳🇱 🇨🇳 — including PLATO ACT 4, STAR-TREC, PRIME-RT & more.
#Radiotherapy #Oncology #GreenJournal
👏 A heartfelt thank you to our top reviewers over the past year at Radiotherapy & Oncology (The Green Journal)!
Your expertise, time, and dedication help uphold the highest standards in our field.
We deeply appreciate your contributions.
#PeerReview #GreenJournal
🔬 New in The Green Journal: RTQA matters.
This first meta-analysis links radiotherapy protocol deviations to worse survival in cancer trials.
OS HR=1.65, PFS HR=1.79.
Real-time QA could improve outcomes sciencedirect.com/science/ar…
#RTQA #Oncology #RadOnc
📢 Just 1 week to go until #ESTRO2025!
The abstract book is live — have you found yours?
👉 user-swndwmf.cld.bz/ESTRO-20…
From AI to adaptive RT, this year’s programme is packed with innovation.
What sessions are you most excited for?
#RadiationOncology #ESTROabstracts
Radiotherapy & Oncology retweeted
Stereotactic reirradiation for in-field lung cancer recurrence after stereotactic ablative radiotherapy - Kevin Jang (@kevjang_)
@RO_GreenJournal
oncodaily.com/science/kevin-…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #SABR #LungCancer #Radiotherapy
🧠 New review sheds light on how to select and delineate post-op radiotherapy target volumes in oral cavity SCC. A must-read for H&N specialists
🔗thegreenjournal.com/article/…
#RadOnc #HeadandNeckCancer #OralCancer #Radiotherapy
1st part of #Radiotherapy Series that deep dives into #PORT for #Headneckcancer
Thanks to @ESTRO_RT and Team led by Profs_Mererid & Vincent with superb colleagues @sueyom @PierluigiBonomo
Part 2 on delineation otw!
Must read for residents!
thegreenjournal.com/article/…
Radiotherapy & Oncology retweeted
Pleased to share our latest work in @RO_GreenJournal
In-field lung re-SABR achieves excellent outcomes with low toxicities.
Size, dose, timing matters. Best results seen in recurrent tumours <2cm, cumulative BED ≥200 Gy, and interval >12 months.
thegreenjournal.com/article/…
🔥 Can SABR work twice?
Meta-analysis shows in-field #SABR reirradiation offers 78% 1-year control with low toxicity—especially for small tumours, high BED (≥200 Gy), & long intervals.
💡 A safe, effective salvage option for recurrent #NSCLC.
📖 thegreenjournal.com/article/…
#radonc
🤖 New in the Green Journal: Most radiation oncology patients support AI/ML in their care — but they want transparency, human connection, and equity.
📄 Read the study: sciencedirect.com/science/ar…
#RadiationOncology #AIinHealthcare #GreenJournal #SocietyMatters #ESTRO
🌍 Society Matters — a new section in the Green Journal!
Exploring how radiation oncology intersects with climate, equity, policy & more.
📖 Read the first editorial: sciencedirect.com/science/ar…
💬 What should we cover next? #RadiationOncology #SocietyMatters #ESTRO #Sustainability
🚨 New study in The Green Journal: Salvage #radiotherapy with VMAT shows promising outcomes for recurrent #ProstateCancer after #HIFU.
✅ Low toxicity
✅ No recurrences during follow-up
✅ A potential standard of care?
thegreenjournal.com/article/…
#Oncology
🚨 Call for Papers! The 4 ESTRO journals are uniting for a landmark issue on reirradiation—a cutting-edge approach offering new hope to patients with recurrent cancers. Submit your research & help shape the future of cancer care! 🔗 thegreenjournal.com/content/… #Reirradiation #RadOnc
📢 New ESTRO-EANO guideline in The Green Journal!
Recommendations for radiotherapy in IDH-mutant WHO grade 2 & 3 diffuse gliomas:
✅ Target volume delineation
✅ Imaging & planning techniques
✅ Dose & fractionation
A must-read for neuro-oncology teams!
thegreenjournal.com/article/…
Check out the latest recommendations for contouring low-grade gliomas – with practical insights on volumes, OARs, and imaging integration.
A must-read for clinical practice and planning optimization.
#RadOnc #NeuroOncology #Contouring #RTplanning
⬇️⬇️⬇️
thegreenjournal.com/article/…
Radiotherapy & Oncology retweeted
Investigator-initiated study sponsored by @JulesBordet and chaired by @AlexDeCaluwe and Laurence Buisseret.
Primary endpoint results presented at #ESMO24 oncologypro.esmo.org/meeting…
🔬 The Neo-CheckRay trial explored pre-op immune-modulating SBRT (8 Gy x 3) + immunotherapy in luminal B breast cancer, sparing tumor-draining lymph nodes to avoid immunosuppression. Feasible, but more research needed! thegreenjournal.com/article/…
#BreastCancer #RadiationOncology
